Next Article in Journal
Vitamin D Analogs Potentiate the Antitumor Effect of Imatinib Mesylate in a Human A549 Lung Tumor Model
Next Article in Special Issue
CREB Negatively Regulates IGF2R Gene Expression and Downstream Pathways to Inhibit Hypoxia-Induced H9c2 Cardiomyoblast Cell Death
Previous Article in Journal
Long-Term Anti-Allodynic Effect of Immediate Pulsed Radiofrequency Modulation through Down-Regulation of Insulin-Like Growth Factor 2 in a Neuropathic Pain Model
Previous Article in Special Issue
miR-134 Modulates the Proliferation of Human Cardiomyocyte Progenitor Cells by Targeting Meis2
Review

Abnormalities in Alternative Splicing of Apoptotic Genes and Cardiovascular Diseases

1
Research, Innovation and Engagements, Mangosuthu University of Technology, Durban 4026, South Africa
2
Department of Biochemistry, Microbiology and Biotechnology, University of Limpopo, Polokwane 0727, South Africa
3
College of Agriculture and Environmental Sciences, Department of Life and Consumer Sciences, Florida Science Campus, University of South Africa, Johannesburg 1709, South Africa
*
Author to whom correspondence should be addressed.
Academic Editor: H. W. M. Niessen
Int. J. Mol. Sci. 2015, 16(11), 27171-27190; https://doi.org/10.3390/ijms161126017
Received: 13 April 2015 / Revised: 6 August 2015 / Accepted: 17 August 2015 / Published: 13 November 2015
(This article belongs to the Special Issue Improvement of Cardiac Function in Heart Failure)
Apoptosis is required for normal heart development in the embryo, but has also been shown to be an important factor in the occurrence of heart disease. Alternative splicing of apoptotic genes is currently emerging as a diagnostic and therapeutic target for heart disease. This review addresses the involvement of abnormalities in alternative splicing of apoptotic genes in cardiac disorders including cardiomyopathy, myocardial ischemia and heart failure. Many pro-apoptotic members of the Bcl-2 family have alternatively spliced isoforms that lack important active domains. These isoforms can play a negative regulatory role by binding to and inhibiting the pro-apoptotic forms. Alternative splicing is observed to be increased in various cardiovascular diseases with the level of alternate transcripts increasing elevated in diseased hearts compared to healthy subjects. In many cases these isoforms appear to be the underlying cause of the disease, while in others they may be induced in response to cardiovascular pathologies. Regardless of this, the detection of alternate splicing events in the heart can serve as useful diagnostic or prognostic tools, while those splicing events that seem to play a causative role in cardiovascular disease make attractive future drug targets. View Full-Text
Keywords: apoptosis; alternative splicing; cardiomyopathies; PUMA; Bcl-2; Bnip3; Nix; therapeutic strategies for targeting heart disease associated abnormal splicing apoptosis; alternative splicing; cardiomyopathies; PUMA; Bcl-2; Bnip3; Nix; therapeutic strategies for targeting heart disease associated abnormal splicing
Show Figures

Graphical abstract

MDPI and ACS Style

Dlamini, Z.; Tshidino, S.C.; Hull, R. Abnormalities in Alternative Splicing of Apoptotic Genes and Cardiovascular Diseases. Int. J. Mol. Sci. 2015, 16, 27171-27190. https://doi.org/10.3390/ijms161126017

AMA Style

Dlamini Z, Tshidino SC, Hull R. Abnormalities in Alternative Splicing of Apoptotic Genes and Cardiovascular Diseases. International Journal of Molecular Sciences. 2015; 16(11):27171-27190. https://doi.org/10.3390/ijms161126017

Chicago/Turabian Style

Dlamini, Zodwa, Shonisani C. Tshidino, and Rodney Hull. 2015. "Abnormalities in Alternative Splicing of Apoptotic Genes and Cardiovascular Diseases" International Journal of Molecular Sciences 16, no. 11: 27171-27190. https://doi.org/10.3390/ijms161126017

Find Other Styles

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop